Lisa Fredriksson, Bram Herpers, Giulia Benedetti, Quraisha Matadin, Jordi C. Puigvert, Hans de Bont, Sanja Dragovic, Nico P.E. Vermeulen, Jan N.M. Commandeur, Erik Danen, Marjo de Graauw, Bob van de Water – 23 March 2011 – Drug‐induced liver injury (DILI) is an important clinical problem. It involves crosstalk between drug toxicity and the immune system, but the exact mechanism at the cellular hepatocyte level is not well understood. Here we studied the mechanism of crosstalk in hepatocyte apoptosis caused by diclofenac and the proinflammatory cytokine tumor necrosis factor α (TNF‐α).

Kai Breuhahn, Gregory Gores, Peter Schirmacher – 23 March 2011 – Over the last decade, numerous small and high‐dimensional profiling analyses have been performed in human hepatocellular carcinoma (HCC), which address different levels of regulation and modulation. Because comprehensive analyses are lacking, the following review summarizes some of the general results and compares them with insights from other tumor entities. Particular attention is given to the impact of these results on future diagnostic and therapeutic approaches. (HEPATOLOGY 2011;)

Maria S. Rosselli, Adriana L. Burgueño, Carlos J. Pirola, Silvia Sookoian – 23 March 2011

Federico Castillo‐Suescun, Gabriel C. Oniscu, Ernest Hidalgo – 21 March 2011 – The presence of large spontaneous splenorenal shunts (SSRSs) is a risk factor for poor portal vein flow and liver dysfunction. The disconnection of splenorenal shunts by left renal vein (LRV) ligation has been suggested as a potential solution for improving portal flow. We reviewed the hemodynamic consequences of splenorenal shunts in deceased donor liver transplantation and investigated the role of LRV ligation.

Brian B. Borg, Anil Seetharam, Vijay Subramanian, Haseeb Ilias Basha, Mauricio Lisker‐Melman, Kevin Korenblat, Christopher D. Anderson, Surendra Shenoy, William C. Chapman, Jeffrey S. Crippin, Thalachallour Mohanakumar – 21 March 2011 – Hepatitis C virus (HCV) infection and its recurrence after orthotopic liver transplantation (OLT) are associated with the remodeling of extracellular matrix (ECM) components [particularly collagen (Col)], which leads to fibrosis.

Jessica Fioravanti, Iranzu González, José Medina‐Echeverz, Esther Larrea, Nuria Ardaiz, Gloria González‐Aseguinolaza, Jesús Prieto, Pedro Berraondo – 21 March 2011 – Interferon alpha (IFNα) is widely used for the treatment of viral hepatitis but substantial toxicity hampers its clinical use. In this work, we aimed at improving the efficacy of IFNα therapy by increasing the IFNα half‐life and providing liver tropism. We selected apolipoprotein A‐I (ApoA‐I) as the stabilizing and targeting moiety.

Long H. Nguyen, Steve Ko, Shane S. Wong, Pelu S. Tran, Huy N. Trinh, Ruel T. Garcia, Aijaz Ahmed, Glen A. Lutchman, Emmet B. Keeffe, Mindie H. Nguyen – 21 March 2011 – Studies of hepatitis B virus (HBV)/hepatitis C virus (HCV) dual infection are limited. Most are small, conducted outside the United States, and compare dual infection with HCV monoinfection. The goal of this study was to characterize HBV/HCV dual infection in a large multiethnic, matched, case‐control study of dual‐infected and HBV‐monoinfected patients at two United States centers.

Babak Azarbal, Paul Poommipanit, Boris Arbit, Antoine Hage, Jignesh Patel, Michelle Kittleson, Saibal Kar, Fady M. Kaldas, Ronald W. Busuttil – 21 March 2011 – Percutaneous coronary intervention (PCI) has traditionally not been an option for patients with end‐stage liver disease (ESLD) and coronary artery disease (CAD). This retrospective study was designed to demonstrate the feasibility and safety of PCI in liver transplant candidates. Patients with ESLD and hemodynamically significant CAD who were otherwise deemed to be acceptable candidates for liver transplantation underwent PCI.

21 March 2011

Stella M. Martínez, Gonzalo Crespo, Miquel Navasa, Xavier Forns – 21 March 2011